Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BETRF BetterLife Pharma	$0.07 -8.2%	$0.07	$0.05 ▼ $0.15	$9.65M	1.52	32,900 shs	28,002 shs
DYAI Dyadic International	$0.94 +2.9%	$1.07	$0.91 ▼ $2.20	$27.44M	0.92	54,903 shs	21,759 shs
NRXP NRx Pharmaceuticals	$3.10 -4.9%	$2.55	$1.10 ▼ $6.01	$56.36M	1.54	413,660 shs	318,957 shs
SCLX Scilex	$4.98 +1.4%	$5.04	$3.60 ▼ $78.05	$34.13M	1.13	66,383 shs	109,832 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BETRF BetterLife Pharma	-8.19%	+0.29%	-15.56%	+8.92%	-24.50%
DYAI Dyadic International	+2.85%	+0.86%	-5.80%	-32.03%	-46.70%
NRXP NRx Pharmaceuticals	-4.91%	-10.92%	+18.32%	+54.23%	+16.98%
SCLX Scilex	+1.43%	+3.97%	+9.45%	-42.90%	-91.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	1.7707 of 5 stars	3.5	2.0	0.0	0.0	0.0	1.7	0.0
NRXP NRx Pharmaceuticals	1.9675 of 5 stars	3.6	1.0	0.0	0.0	2.5	0.8	0.6
SCLX Scilex	2.0927 of 5 stars	3.3	2.0	0.0	0.0	2.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BETRF BetterLife Pharma	0.00	N/A	N/A	N/A
DYAI Dyadic International	3.00	Buy	$6.00	539.66% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	819.35% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	9,036.55% Upside

Current Analyst Ratings Breakdown

Latest BETRF, SCLX, DYAI, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/11/2025	SCLX Scilex	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
4/2/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$770.00 ➝ $630.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	($0.04) per share	N/A
DYAI Dyadic International	$3.49M	8.09	N/A	N/A	$0.08 per share	11.73
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
SCLX Scilex	$56.59M	0.61	N/A	N/A	($27.68) per share	-0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BETRF BetterLife Pharma	-$2.55M	-$0.02	N/A	∞	N/A	N/A	N/A	-1,124.01%	6/25/2025 (Estimated)
DYAI Dyadic International	-$5.81M	-$0.20	N/A	N/A	N/A	-163.94%	-233.69%	-59.37%	8/12/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-146.93%	N/A	-82.65%	8/12/2025 (Estimated)

Latest BETRF, SCLX, DYAI, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/14/2025	Q1 2025	DYAI Dyadic International	N/A	-$0.07	N/A	-$0.07	N/A	$0.39 million
3/26/2025	Q4 2024	DYAI Dyadic International	-$0.04	-$0.05	-$0.01	-$0.05	$1.60 million	$0.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BETRF BetterLife Pharma	N/A	0.03	0.03
DYAI Dyadic International	5.40	3.98	3.98
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
SCLX Scilex	N/A	0.10	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BETRF BetterLife Pharma	0.01%
DYAI Dyadic International	27.95%
NRXP NRx Pharmaceuticals	4.27%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
BETRF BetterLife Pharma	34.77%
DYAI Dyadic International	29.50%
NRXP NRx Pharmaceuticals	19.00%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BETRF BetterLife Pharma	7	129.46 million	84.45 million	Not Optionable
DYAI Dyadic International	7	30.09 million	21.21 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
SCLX Scilex	80	6.95 million	6.40 million	Optionable

BETRF, SCLX, DYAI, and NRXP Headlines

Recent News About These Companies

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23 at 4:50 PM | globenewswire.com

Scilex (NASDAQ:SCLX) Shares Down 3.1% - Time to Sell?

June 18, 2025 | americanbankingnews.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

April 15, 2025 | globenewswire.com

Scilex announces 1-for-35 reverse stock split

April 12, 2025 | markets.businessinsider.com

D. Boral Capital Downgrades Scilex Holding (SCLX)

April 12, 2025 | msn.com

Scilex downgraded to Hold from Buy at D. Boral Capital

April 11, 2025 | msn.com

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

April 11, 2025 | globenewswire.com

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

March 26, 2025 | globenewswire.com

Scilex Holding Company Announces Change of Record Date for Preferred Stock Dividend

March 12, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, SCLX, DYAI, and NRXP Company Descriptions

BetterLife Pharma OTCMKTS:BETRF

$0.07 -0.01 (-8.19%)

As of 06/23/2025 03:33 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Dyadic International NASDAQ:DYAI

$0.94 +0.03 (+2.85%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.01 (+1.49%)

As of 06/23/2025 04:01 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

NRx Pharmaceuticals NASDAQ:NRXP

$3.10 -0.16 (-4.91%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$3.14 +0.03 (+1.13%)

As of 05:16 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Scilex NASDAQ:SCLX

$4.98 +0.07 (+1.43%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$5.00 +0.02 (+0.40%)

As of 07:00 AM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time